LIPID Study
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
LIPID Study On the Web |
|
American Roentgen Ray Society Images of LIPID Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To assess the efficacy of pravastatin in reducing mortality in known CAD patients.
Methods
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study was a randomized, double-blinded, placebo controlled trial wherein 9014 patients (young and old) with known CAD and total cholesterol levels in the range of 155 to 271 mg per deciliter were enrolled and randomly assigned to treatment with either 40 mg daily pravastatin or placebo. The patients were followed up for a mean period of 6.1 years.
Results
- Pravastatin was associated with a lower rate of death from CAD compared with placebo (6.4% vs 8.3%)
- Overall mortality rate was lower in the pravastatin group compared with that in the placebo group (11% vs 14.1%)
- The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin
Conclusion
Treatment with pravastatin reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.[1]
References
- ↑ "Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group". The New England Journal of Medicine. 339 (19): 1349–57. 1998. doi:10.1056/NEJM199811053391902. PMID 9841303. Unknown parameter
|month=ignored (help)